Human Clinical Trials in Lupus Nephritis

Seminars in Nephrology

Volumn 27, Issue 1, 2007, Pages 115-127

  Dooley, Mary Anne ^a   Falk, Ronald J ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

autoimmunity; Glomerulonephritis; immunosuppressive therapy; lupus nephritis; mycophenolate mofetil

Indexed keywords

ABATACEPT; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; EPRATUZUMAB; GLUCOCORTICOID; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB;

ARTICLE; CLINICAL TRIAL; DIARRHEA; DISEASE CLASSIFICATION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HIGH RISK POPULATION; HUMAN; INFECTION; LONG TERM CARE; LUPUS ERYTHEMATOSUS NEPHRITIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RELAPSE; REMISSION; RENAL REPLACEMENT THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MYCOPHENOLIC ACID; PROGNOSIS;

EID: 33847330179     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2006.09.011     Document Type: Article

References (63)

1. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25 (1982) 1271-1277
2. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40 (1997) 1725
3. Dooley M.A., Aranow C., and Ginzler E.M. Review of ACR renal criteria in systemic lupus erythematosus. Lupus 13 (2004) 857-860
4. Appel G.B., Cohen D.J., Pirani C.L., Meltzer J.I., and Estes D. Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med 83 (1987) 877-885
5. Donadio Jr. J.V., Hart G.M., Bergstralh E.J., and Holley K.E. Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus 4 (1995) 109-115
6. Walsh S.J., Algert C., Gregorio D.I., Reisine S.T., and Rothfield N.F. Divergent racial trends in mortality from systemic lupus erythematosus. J Rheumatol 22 (1995) 1663-1668
7. Arnett F.C., Hamilton R.G., Roebber M.G., Harley J.B., et al. Increased frequencies of Sm and nRNP autoantibodies in American blacks compared to whites with systemic lupus erythematosus. J Rheumatol 15 (1988) 1773-1776
8. Cooper G.S., Parks C.G., Treadwell E.L., St Clair E.W., et al. Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States. Lupus 11 (2002) 161-167
9. Barr R.G., Seliger S., Appel G.B., Zuniga R., et al. Prognosis in proliferative lupus nephritis: role of race and socioeconomic status. Nephrol Dial Transplant 18 (2003) 2039-2046
10. Nissenson A.R., and Port F.K. Outcome of end-stage renal disease in patients with rare causes of renal failure. III. Systemic/vascular disorders. QJM 74 (1990) 63-74
11. Active Projects Report: Research and Demonstrations in Health Care Financing. Centers for Medicare and Medicaid Services. U.S. Department of Health and Human Services. 2006 [cited 2007 January 10]. Available from: www.cms.hhs.gov/ESRDProfileTables/50_CausesList.asp.
12. Dooley M.A. Lupus nephritis. In: Wallace D.J., and Hahn B.H. (Eds). DuBois' lupus erythematosus. 7th ed. (2001), Lippincott Williams & Wilkins, Philadelphia 1113
13. Maddison P., Farewell V., Isenberg D., Aranow C., et al. The rate and pattern of organ damage in late onset systemic lupus erythematosus. J Rheumatol 29 (2002) 913-917
14. Prasad R., Ibanez D., Gladman D., Urowitz M., et al. Anti-dsDNA and anti-Sm antibodies do not predict damage in systemic lupus erythematosus. Lupus 15 (2006) 285-291
15. Hill G.S., Delahousse M., Nochy D., and Bariety J. Class IV-S versus class IV-G lupus nephritis: clinical and morphologic differences suggesting different pathogenesis. Kidney Int 68 (2005) 2288-2297
16. Mittal B., Hurwitz S., Rennke H., and Singh A.K. New subcategories of class IV lupus nephritis: are there clinical, histologic, and outcome differences?. Am J Kidney Dis 44 (2004) 1050-1059
17. Yokoyama H., Wada T., Hara A., Yamahana J., et al., Kanazawa Study Group for Renal Diseases and Hypertension. The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese. Kidney Int 66 (2004) 2382-2388
18. Bastian H.M., Roseman J.M., McGwin Jr. G., Alarcon G.S., et al. Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 11 (2002) 152-160
19. Reveille J.D., Goodman R.E., Barger B.O., Acton R.T., et al. Familial polyarteritis nodosa: a serologic and immunogenetic analysis. J Rheumatol 16 (1989) 181-185
20. Sprovieri S.R., Sens Y.A., and Martini F.D. Association between polymorphisms of the renin-angiotensin system and more severe histological forms of lupus nephritis. Clin Nephrol 64 (2005) 20-27
21. Lee Y.H., Rho Y.H., Choi S.J., Ji J.D., et al. Angiotensin-converting enzyme insertion/deletion polymorphism and systemic lupus erythematosus: a metaanalysis. J Rheumatol 33 (2006) 698-702
22. Sanchez E., Morales S., Paco L., Lopez-Nevot M.A., et al. Interleukin 12 (IL12B), interleukin 12 receptor (IL12RB1) and interleukin 23 (IL23A) gene polymorphism in systemic lupus erythematosus. Rheumatology (Oxford) 44 (2005) 1136-1139
23. Smyth D.J., Howson J., Payne F., Maier L.M., et al. Analysis of polymorphisms in 16 genes in type 1 diabetes that have been associated with other immune-mediated diseases. BMC Med Genet 7 (2006) 20-32
24. Kochi Y., Yamada R., Suzuki A., Harley J.B., et al. A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities. Nat Genet 37 (2005) 478-485
25. Criswell L.A., Pfeiffer K.A., Lum R.F., Gonzalez B., et al. Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am J Hum Genet 76 (2005) 561-571
26. Cappione III A., Anolik J.H., Pugh-Bernard A., Barnard J., et al. Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J Clin Invest 115 (2005) 3205-3216
27. Katsiari C.G., Kyttaris V.C., Juang Y.T., Tsokos G.C., et al. Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus. J Clin Invest 115 (2005) 3193-3204
28. Juang Y.T., Wang Y., Solomou E.E., Li Y., et al. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J Clin Invest 115 (2005) 996-1005
29. Chan R.W., Lai F.M., Li E.K., Tam L.S., et al. Imbalance of Th1/Th2 transcription factors in patients with lupus nephritis. Rheumatology (Oxford) 45 (2006) 951-957
30. Falk R.J., Hogan S., Carey T.S., Jennette J.C., et al., The Glomerular Disease Collaborative Network. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. Ann Intern Med 113 (1990) 656-663
31. Schlesinger N., Schlesinger M., and Seshan S.V. Seasonal variation of lupus nephritis: high prevalence of class V lupus nephritis during the winter and spring. J Rheumatol 32 (2005) 1053-1057
32. Moroni G., Gallelli B., Quaglini S., Banfi G., et al. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol Dial Transplant 21 (2006) 1541-1548
33. Barber C.E., Geldenhuys L., and Hanly J.G. Sustained remission of lupus nephritis. Lupus 15 (2006) 94-101
34. Dooley M.A., Hogan S., Jennette C., Falk R.J., et al., Glomerular Disease Collaborative Network. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Kidney Int 51 (1997) 1188-1195
35. Moroni G., Tantardini F., Gallelli B., Qaglini S., et al. The long-term prognosis of renal transplantation in patients with lupus nephritis. Am J Kidney Dis 45 (2005) 903-911
36. Balow J.E., and Austin III H.A. Treatment of proliferative lupus nephritis. Am J Kidney Dis 43 (2004) 383-385
37. Esdaile J.M., Joseph L., MacKenzie T., et al. The benefit of early treatment with immunosuppressive drugs in lupus nephritis. J Rheumatol 22 (1995) 1211
38. Kanda H., Kubo K., Tateishi S., Sato K., et al. Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy. Lupus 14 (2005) 288-292
39. Tse K.C., Li F.K., Tang S., Tang C.S., et al. Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria. Lupus 14 (2005) 947-952
40. Mok C.C., Ying K.Y., Ng W.L., et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 119 (2006) 355.e25-355.e33
41. Chan T.M., Li F.K., Tang C.S., et al., Hong Kong-Guangzhou Nephrology Study Group. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 343 (2000) 1156-1162
42. Falk R.J. Treatment of lupus nephritis-a work in progress. N Engl J Med 343 (2000) 1182-1183
43. Cross J., Dwomoa A., Andrews P., et al. Mycophenolate mofetil for remission induction in severe lupus nephritis. Nephron Clin Pract 100 (2005) c92-c100
44. Karim M.Y., Pisoni C.N., Ferro L., et al. Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. Rheumatology (Oxford) 44 (2005) 1317-1321
45. Pisoni C.N., Karim Y., and Cuadrado M.J. Mycophenolate mofetil and systemic lupus erythematosus: an overview. Lupus 14 Suppl 1 (2005) s9-s11
46. Chan T.M., Tse K.C., Tang C.S., et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 16 (2005) 1076-1084
47. Ong L.M., Hooi L.S., Lim T.O., et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton) 10 (2005) 504-510
48. Contreras G., Tozman E., Nahar N., et al. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide. Lupus 14 Suppl 1 (2005) s33-s38
49. Ginzler E.M., Dooley M.A., Aranow C., et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353 (2005) 2219-2228
50. Kasitanon N., Fine D.M., Haas M., Magder L.S., and Petri M. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 15 (2006) 366-370
51. Hsu C.L., Chen K.Y., Yeh P.S., et al. Outcome and prognostic factors in critically ill patients with systemic lupus erythematosus: a retrospective study. Crit Care 9 (2005) R177-R183
52. Thatayatikom A., and White A.J. Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun Rev 5 (2006) 18-24
53. Anolik J.H., and Aringer M. New treatments for SLE: cell-depleting and anti-cytokine therapies. Best Pract Res Clin Rheumatol 19 (2005) 859-878
54. Wallace D.J., and Tumlin J.A. LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus. Lupus 13 (2004) 323-327
55. Riboldi P., Gerosa M., Moroni G., et al. Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus?. Autoimmunity 38 (2005) 39-45
56. Migliorini P., Baldini C., Rocchi V., et al. Anti-Sm and anti-RNP antibodies. Autoimmunity 38 (2005) 47-54
57. Mahler M., Stinton L.M., and Fritzler M.J. Improved serological differentiation between systemic lupus erythematosus and mixed connective tissue disease by use of an SmD3 peptide-based immunoassay. Clin Diagn Lab Immunol 12 (2005) 107-113
58. Sinico R.A., Radice A., Ikehata M., et al. Anti-C1q autoantibodies in lupus nephritis: prevalence and clinical significance. Ann N Y Acad Sci 1050 (2005) 193-200
59. Marto N., Bertolaccini M.L., Calabuig E., et al. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis 64 (2005) 444-448
60. Trendelenburg M. Antibodies against C1q in patients with systemic lupus erythematosus. Springer Semin Immunopathol 27 (2005) 276-285
61. Trouw L.A., and Daha M.R. Role of anti-C1q autoantibodies in the pathogenesis of lupus nephritis. Expert Opin Biol Ther 5 (2005) 243-251
62. Meller S., Winterberg F., Gilliet M., et al. Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum 52 (2005) 1504-1516
63. Rovin B.H., Song H., Hebert L.A., et al. Plasma, urine, and renal expression of adiponectin in human systemic lupus erythematosus. Kidney Int 68 (2005) 1825-1833